Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology. Chem Cent J (2017) 0.75

Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion. Stem Cell Res Ther (2015) 0.75

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

The druggable genome. Nat Rev Drug Discov (2002) 13.61

Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95

Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09

Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26

The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00

Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91

The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther (2007) 7.08

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med (2003) 6.68

Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60

Drug delivery and targeting. Nature (1998) 6.16

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev (2001) 5.06

Global mapping of pharmacological space. Nat Biotechnol (2006) 4.99

Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90

Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev (2001) 4.52

Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today (2006) 4.24

Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces (2009) 4.06

Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol (2009) 3.41

Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev (2005) 3.39

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30

A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release (2008) 3.27

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem (2011) 2.97

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res (2004) 2.90

Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78

Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73

Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev (2005) 2.56

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood (2006) 2.55

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood (2007) 2.53

Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res (2001) 2.50

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37

Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35

Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett (2010) 2.35

Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35

Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res (2000) 2.30

Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19

Matrix metalloproteinases in tumor-host cell communication. Differentiation (2002) 2.16

The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06

The genetic basis for cancer treatment decisions. Cell (2012) 2.03

Nanotechnology for the biologist. J Leukoc Biol (2005) 2.03

Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci (2004) 1.98

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci (2009) 1.98

Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl (2008) 1.94

Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl (2009) 1.93

Targeting nanoparticles to cancer. Pharmacol Res (2010) 1.88

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.68

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol (2012) 1.68

Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) (2008) 1.67

Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer (2007) 1.65

Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res (2011) 1.54

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat (2011) 1.51

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res (2008) 1.51

Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev (2009) 1.49

Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res (2008) 1.46

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res (2008) 1.45

Dendrimer toxicity: Let's meet the challenge. Int J Pharm (2010) 1.44

Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol (2010) 1.44

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol (2008) 1.43

The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials (2009) 1.37

Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials (2011) 1.36

Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials (2009) 1.34

Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) (2008) 1.33

Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl (2007) 1.32

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol (2012) 1.32

Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30

Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res (1995) 1.29

Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials (2010) 1.29

Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27

Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci (2007) 1.27

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release (2009) 1.24

Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials (2009) 1.24

Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull (2006) 1.23

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res (2008) 1.22

A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine (2011) 1.20

Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys (2007) 1.20

Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19

Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol (1990) 1.19

Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene (2010) 1.19

Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19

Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release (2006) 1.18